What we do Divi's Laboratories Ltd is a leading global pharmaceutical company specializing in manufacturing Active Pharmaceutical Ingredients, intermediates, and nutraceuticals with a strong export focus. |
Founded in 1,990 |
Market share Among the world's largest API manufacturers with presence in over 100 countries and a portfolio of approx. 160 products across diverse therapeutic areas. |
Problem solved Provides reliable, high-quality pharmaceutical ingredients and custom synthesis services supporting generic and innovator pharma companies globally. |
Top clients or who we serve Serves global pharmaceutical companies including MNCs; operates B2B model supplying APIs and nutraceutical ingredients worldwide. |
Key management Dr. Murali K. Divi, Managing Director; Dr. Kiran S. Divi, CEO; Mr. N.V. Ramana, Executive Director—all experienced leaders steering growth. |
Our journey and innovations Founded in 1990 focusing on R&D; expanded with multiple manufacturing units and SEZs; pioneer in custom synthesis and backward integration. |
Where we operate Global footprint with manufacturing in India and subsidiaries in USA and Switzerland, serving markets across India, USA, Europe, and other countries. |
Top products or what we offer APIs, pharma intermediates, custom synthesis, and nutraceutical ingredients supporting a broad range of therapeutic segments. |
Top brands Not specifically branded products; recognized globally for quality APIs and custom synthesis services with strong regulatory approvals. |
Raw materials needed Chemical intermediates and raw materials for synthesis of pharmaceutical APIs and nutraceutical compounds. |
Raw materials supplier Supplied by various domestic and international chemical manufacturers under strict quality controls. |
Recurring vs cyclical contribution Revenue primarily recurring through long-term contracts with pharmaceutical clients supporting stable growth. |
Our industry position Market leader among Indian API manufacturers with significant global market share and strong regulatory track record. |
Financial highlights FY 2024-25 revenue Rs 9,360 crore; Profit after tax Rs 2,191 crore; consistent double-digit growth over prior year. |
Geographical revenue split Revenue from Other countries Rs 5,039 Cr, Switzerland Rs 1,908 Cr, USA Rs 1,306 Cr, India Rs 1,107 Cr in FY25. |
Order book Strong order pipeline supported by capacity expansions in SEZ units and new greenfield manufacturing facility at Kakinada. |
Whats driving growth Expansion in manufacturing capabilities, increasing demand for APIs, custom synthesis projects, and global pharmaceutical industry growth. |
Our future plans Scaling new units at Kakinada, enhancing existing SEZ plants, and capitalizing on custom synthesis to drive future growth. |
Our green promise Investments in modern waste treatment and sustainable manufacturing practices aligning with environmental responsibilities. |
Our people and values Over 9,000 employees focused on innovation, quality, safety, and corporate governance fostering inclusive work culture. |
Key challenges ahead Regulatory compliance, global supply chain risks, and intense competition from emerging API manufacturers. |
Interesting facts One of the few Indian API companies with multiple US FDA cleared plants and international regulatory certifications. |
Risks and strategy Mitigates risks via diversified products, robust compliance, backward integration, and sustained R&D investment. |
